Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 + Pucotenlimab + Axitinib in Advanced Melanoma with Liver Metastasis
NCT05070221Phase 1Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
Phase 1, open-label trial of OH2 in melanoma (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
OH2
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05070221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070221.